Baylor College of Medicine, Texas Children's Hospital, Houston, Texas.
Health Informatics Institute, University of South Florida, Tampa, Florida.
J Clin Endocrinol Metab. 2020 Dec 1;105(12):e4393-406. doi: 10.1210/clinem/dgaa348.
We set forth to compare ethnicities for metabolic and immunological characteristics at the clinical diagnosis of type 1 diabetes (T1D) and assess the effect of ethnicity on beta-cell functional loss within 3 years after clinical diagnosis.
We studied participants in TrialNet New Onset Intervention Trials (n = 624, median age = 14.4 years, 58% male, 8.7% Hispanic) and followed them prospectively for 3 years. Mixed meal tolerance tests (MMTT) were performed within 6 months following clinical diagnosis and repeated semiannually. Unless otherwise indicated, analyses were adjusted for age, sex, BMI Z-score, and diabetes duration.
At T1D clinical diagnosis, Hispanics, compared with non-Hispanic whites (NHW), had a higher frequency of diabetic ketoacidosis (DKA) (44.7% vs 25.3%, OR = 2.36, P = 0.01), lower fasting glucose (97 vs 109 mg/dL, P = 0.02) and higher fasting C-peptide (1.23 vs 0.94 ng/mL, P = 0.02) on the first MMTT, and higher frequency of ZnT8 autoantibody positivity (n = 201, 94.1% vs 64%, OR = 7.98, P = 0.05). After exclusion of participants in experimental arms of positive clinical trials, C-peptide area under the curve (AUC) trajectories during the first 3 years after clinical diagnosis were not significantly different between Hispanics and NHW after adjusting for age, sex, BMI-z score, and DKA (n = 413, P = 0.14).
Despite differences in the metabolic and immunological characteristics at clinical diagnosis of T1D between Hispanics and NHW, C-peptide trajectories did not differ significantly in the first 3 years following clinical diagnosis after adjustment for body mass index and other confounders. These findings may inform the design of observational studies and intervention trials in T1D.
我们旨在比较 1 型糖尿病(T1D)临床诊断时不同种族人群的代谢和免疫特征,并评估种族对临床诊断后 3 年内胰岛β细胞功能丧失的影响。
我们研究了参与 TrialNet 新发干预试验(n=624,中位年龄 14.4 岁,58%为男性,8.7%为西班牙裔)的参与者,并对他们进行了前瞻性随访 3 年。在临床诊断后 6 个月内进行混合餐耐量试验(MMTT),并每半年重复一次。除非另有说明,分析结果均经过年龄、性别、BMI Z 评分和糖尿病病程的调整。
在 T1D 临床诊断时,与非西班牙裔白人(NHW)相比,西班牙裔人群发生糖尿病酮症酸中毒(DKA)的频率更高(44.7% vs. 25.3%,OR=2.36,P=0.01),空腹血糖更低(97 vs. 109mg/dL,P=0.02),空腹 C 肽更高(1.23 vs. 0.94ng/mL,P=0.02),锌转运体 8 自身抗体阳性的频率更高(n=201,94.1% vs. 64%,OR=7.98,P=0.05)。排除阳性临床试验实验组参与者后,在校正年龄、性别、BMI-z 评分和 DKA 后(n=413),西班牙裔和 NHW 人群在临床诊断后 3 年内的 C 肽 AUC 轨迹在调整后并无显著差异(P=0.14)。
尽管西班牙裔和 NHW 人群在 T1D 临床诊断时的代谢和免疫特征存在差异,但在调整体重指数和其他混杂因素后,临床诊断后 3 年内 C 肽轨迹并无显著差异。这些发现可能为 T1D 的观察性研究和干预试验设计提供信息。